These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 33790661)

  • 1. Experimental Pharmacotherapy for Dry Eye Disease: A Review.
    Baiula M; Spampinato S
    J Exp Pharmacol; 2021; 13():345-358. PubMed ID: 33790661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tivanisiran, a novel siRNA for the treatment of dry eye disease.
    Moreno-Montañés J; Bleau AM; Jimenez AI
    Expert Opin Investig Drugs; 2018 Apr; 27(4):421-426. PubMed ID: 29569947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies.
    Shen Lee B; Kabat AG; Bacharach J; Karpecki P; Luchs J
    Clin Ophthalmol; 2020; 14():119-126. PubMed ID: 32021076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysregulated Tear Fluid Nociception-Associated Factors, Corneal Dendritic Cell Density, and Vitamin D Levels in Evaporative Dry Eye.
    Khamar P; Nair AP; Shetty R; Vaidya T; Subramani M; Ponnalagu M; Dhamodaran K; D'souza S; Ghosh A; Pahuja N; Deshmukh R; Ahuja P; Sainani K; Nuijts RMMA; Das D; Ghosh A; Sethu S
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2532-2542. PubMed ID: 31195410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Narrative Review of Current Understanding and Classification of Dry Eye Disease with New Insights on the Impact of Dry Eye during the COVID-19 Pandemic.
    Barabino S
    Ophthalmol Ther; 2021 Sep; 10(3):495-507. PubMed ID: 34275088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rethinking dry eye disease: a perspective on clinical implications.
    Bron AJ; Tomlinson A; Foulks GN; Pepose JS; Baudouin C; Geerling G; Nichols KK; Lemp MA
    Ocul Surf; 2014 Apr; 12(2 Suppl):S1-31. PubMed ID: 24725379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular evidence for the role of inflammation in dry eye disease.
    Ganesalingam K; Ismail S; Sherwin T; Craig JP
    Clin Exp Optom; 2019 Sep; 102(5):446-454. PubMed ID: 30630216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study.
    Sacchetti M; Lambiase A; Schmidl D; Schmetterer L; Ferrari M; Mantelli F; Allegretti M; Garhoefer G
    Br J Ophthalmol; 2020 Jan; 104(1):127-135. PubMed ID: 30944103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining Dry Eye from a Clinical Perspective.
    Tsubota K; Pflugfelder SC; Liu Z; Baudouin C; Kim HM; Messmer EM; Kruse F; Liang L; Carreno-Galeano JT; Rolando M; Yokoi N; Kinoshita S; Dana R
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease.
    Semba CP; Gadek TR
    Clin Ophthalmol; 2016; 10():1083-94. PubMed ID: 27354762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hot Topics in Dry Eye Disease.
    Chiaradia PA; Zeman Bardeci LA; Dankert S; Mendaro MO; Grzybowski A
    Curr Pharm Des; 2017; 23(4):608-623. PubMed ID: 27928967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dry Eye Disease: Early Recognition with Guidance on Management and Treatment for Primary Care Family Physicians.
    Verjee MA; Brissette AR; Starr CE
    Ophthalmol Ther; 2020 Dec; 9(4):877-888. PubMed ID: 33090327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting.
    Baudouin C; Irkeç M; Messmer EM; Benítez-Del-Castillo JM; Bonini S; Figueiredo FC; Geerling G; Labetoulle M; Lemp M; Rolando M; Van Setten G; Aragona P;
    Acta Ophthalmol; 2018 Mar; 96(2):111-119. PubMed ID: 28390092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential New Target for Dry Eye Disease-Oxidative Stress.
    Bu J; Liu Y; Zhang R; Lin S; Zhuang J; Sun L; Zhang L; He H; Zong R; Wu Y; Li W
    Antioxidants (Basel); 2024 Mar; 13(4):. PubMed ID: 38671870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of dry eye disease treatment on patient satisfaction and quality of life: A review.
    Gomes JAP; Santo RM
    Ocul Surf; 2019 Jan; 17(1):9-19. PubMed ID: 30419303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The environment and dry eye-manifestations, mechanisms, and more.
    Patel S; Mittal R; Kumar N; Galor A
    Front Toxicol; 2023; 5():1173683. PubMed ID: 37681211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study design and baseline findings from the progression of ocular findings (PROOF) natural history study of dry eye.
    McDonnell PJ; Pflugfelder SC; Stern ME; Hardten DR; Conway T; Villanueva L; Hollander DA
    BMC Ophthalmol; 2017 Dec; 17(1):265. PubMed ID: 29284427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting.
    Baudouin C; Aragona P; Messmer EM; Tomlinson A; Calonge M; Boboridis KG; Akova YA; Geerling G; Labetoulle M; Rolando M
    Ocul Surf; 2013 Oct; 11(4):246-58. PubMed ID: 24112228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tear Proteomics Approach to Monitoring Sjögren Syndrome or Dry Eye Disease.
    Kuo MT; Fang PC; Chao TL; Chen A; Lai YH; Huang YT; Tseng CY
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31010136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments.
    Periman LM; Mah FS; Karpecki PM
    Clin Ophthalmol; 2020; 14():4187-4200. PubMed ID: 33299295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.